EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Tremor outcomes after conversion from immediate-release to LCP tacrolimus in lung transplant recipients: a randomized controlled trial

Niels L. Riemersma, Heleen Grootjans, Daan Kremer, Janna Alkema, Cheryl S. J. Everlo, A. Madelein M. van der Stouwe, Willie N. Steenhuis, Erik A. M. Verschuuren, Huib A. M. Kerstjens, Stefan P. Berger, Stephan J. L. Bakker, C. Tji Gan

Transplant International · 06.11.2026 · 39

DOI: 10.3389/ti.2026.17034 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Transplant International, online erschienen am 06.11.2026. Verfasst von Niels L. Riemersma und 11 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tremor is an important, dose-dependent side effect of tacrolimus in lung transplant (LTx) recipients. We assessed whether once-daily extended-release Life Cycle Pharma (LCP) tacrolimus with lower peak concentrations results in less tremor compared with twice-daily immediate-release (IR) tacrolimus. The prospective, randomized, controlled REVOLUTION trial (NCT05001074) randomized LTx recipients to either continue IR-tacrolimus or to switch to LCP-tacrolimus. Tremor was assessed with linear mixed models, objectively with the Fahn-Tolosa-Marin Tremor Rating Scale part B and subjectively with a Visual Analog Scale, at baseline and after 1 and 2 years. We included 65 LTx recipients (56.9% men; median age: 61.8 [45.0–66.6] years), with a median of 4.9 [2.1–8.1] years having passed since their transplantation. Baseline tremor severity did not differ significantly between groups (objective tremor: IR: 5.5 [3.5–8.0] vs. LCP: 6.8 [5.5–8.3]; p = 0.3 and subjective tremor: IR: 10.0 [5.0–30.0] vs. LCP: 20.0 [10.0–30.0], p = 0.1). Tremor severity remained similar between groups over time after adjusting for age, time since transplantation, tacrolimus trough levels, and kidney function. Higher age and higher tacrolimus trough levels were associated with greater objective tremor severity (β = 0.22, p = 0.001 and β = 0.21, p = 0.036, respectively). This is, to our knowledge, the first randomized clinical trial in lung transplant recipients to evaluate the effect of conversion from IR to LCP tacrolimus on tremor severity showing no effect. Clinical Trial Registration ClinicalTrials.gov , identifier NCT05001074.

Zitieren

APA

Riemersma, N. L., Grootjans, H., Kremer, D., Alkema, J., Everlo, C. S. J., Stouwe, A. M. M. V. D., Steenhuis, W. N., Verschuuren, E. A. M., Kerstjens, H. A. M., Berger, S. P., Bakker, S. J. L., & Gan, C. T. (2026). Tremor outcomes after conversion from immediate-release to LCP tacrolimus in lung transplant recipients: a randomized controlled trial. Transplant International, 39. https://doi.org/10.3389/ti.2026.17034

Vancouver

Riemersma NL, Grootjans H, Kremer D, Alkema J, Everlo CSJ, Stouwe AMMVD, et al. Tremor outcomes after conversion from immediate-release to LCP tacrolimus in lung transplant recipients: a randomized controlled trial. Transplant International. 2026;39. doi:10.3389/ti.2026.17034

BibTeX
@article{Riemersma2026,
  author = {Riemersma, Niels L. and Grootjans, Heleen and Kremer, Daan and Alkema, Janna and Everlo, Cheryl S. J. and Stouwe, A. Madelein M. van der and Steenhuis, Willie N. and Verschuuren, Erik A. M. and Kerstjens, Huib A. M. and Berger, Stefan P. and Bakker, Stephan J. L. and Gan, C. Tji},
  title = {Tremor outcomes after conversion from immediate-release to LCP tacrolimus in lung transplant recipients: a randomized controlled trial},
  journal = {Transplant International},
  year = {2026},
  volume = {39},
  doi = {10.3389/ti.2026.17034}
}
Kostenlos starten →